RxDoctor Payments DataLook up a doctor →

Ghulam Abbas, MD

Family Medicine · Washington, DCNPI 1427379049

Payments from drug & device makers

$8,766in general payments, 2019–2025

Across 401 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Pfizer$984
  • Novo Nordisk$893
  • Viiv Healthcare Company$694
  • Gilead$685
  • Lilly USA, LLC$592
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$8,754100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,766 in reported general payments places this provider in the 95th percentile of 166 family medicine providers in District of Columbia.

See all family medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$138,327
Medicare patients
355
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban52$55,567
JardianceEmpagliflozin35$47,878
JanuviaSitagliptin Phosphate21$26,997
OzempicSemaglutide15$25,429
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,244
SymbicortBudesonide/Formoterol Fumarate19$4,403
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide85$4,122
Atorvastatin Calcium250$3,304
Rosuvastatin Calcium168$2,612
Amlodipine Besylate317$2,394
Colchicine17$2,332
Olmesartan Medoxomil88$1,941
Levothyroxine Sodium112$1,674
PaxlovidNirmatrelvir/Ritonavir13$1,429
Metformin Hcl130$1,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$984$56,99665 claims
MerckJanuvia$124$26,99721 claims
Novo NordiskOzempic$893$25,42915 claims
AstraZenecaSymbicort$228$4,40319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 family medicine providers in District of Columbia.

Other family medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →